Big Pharma vs. Compounders: GLP-1 Drugs' Safety Debate
Vancouver News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Big pharma vs. compounders: The battle over GLP-one drugs for obesity and diabetes - Drug companies like Novo Nordisk are pushing for restrictions on cheaper compounded versions of GLP-one drugs, citing safety concerns. However, critics argue that the FDAs self-reporting system, FAERS, has serious flaws and may overstate risks. Pharmacy advocates and doctors are fighting back, stressing the need for better monitoring of all drugs. Studies on approved GLP-one drugs show mixed results, with some older ones linked to thousands of reported deaths, while recent research found they cut colon cancer death risk by more than half in some patients. Despite the shortage being declared over, access remains difficult due to high costs and limited insurance coverage.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/6276d6924eecec87